Improvement in HbA1c, reduction in ER visits and hospitalizations for hypoglycemia seen in insulin-treated patients with diabetes<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, June 3, 2021 (HealthDay News) — For insulin-treated patients with diabetes, real-time continuous glucose monitoring (CGM) is associated with improvements in hemoglobin A1c (HbA1c) and reductions in emergency department visits and hospitalizations for hypoglycemia, according to a study published online June 2 in the Journal of the American Medical Association<\/em>.<\/p>\n Andrew J. Karter, Ph.D., from Kaiser Permanente in Oakland, California, and colleagues estimated clinical outcomes of real-time CGM initiation in a cohort of 41,753 participants with insulin-treated diabetes (5,673 with type 1 diabetes and 36,080 with type 2 diabetes). Ten end points were measured during the 12 months before and after baseline among 3,806 CGM initiators and 37,947 noninitiators.<\/p>\n The researchers found that mean HbA1c decreased from 8.17 to 7.76 percent among CGM initiators and from 8.28 to 8.19 percent among noninitiators (adjusted difference-in-differences estimate, \u00e2\u0088\u00920.40 percent). Hypoglycemia (emergency department or hospital utilization) rates decreased among CGM initiators (5.1 to 3.0 percent) and increased among noninitiators (1.9 to 2.3 percent; difference-in-differences estimate, \u00e2\u0088\u00922.7 percent). Statistically significant differences were observed in the adjusted net changes in the proportion of patients with HbA1c lower than 7 percent, lower than 8 percent, and higher than 9 percent (adjusted difference-in-differences estimates, 9.6, 13.1, and \u00e2\u0088\u00927.1 percent, respectively); there were also statistically significant differences in the number of outpatient visits and telephone visits (adjusted difference-in-differences estimates, \u00e2\u0088\u00920.4 and 1.1).<\/p>\n “In this observational study, patients selected by clinicians for real-time CGM initiation achieved improved glycemic control and lower hypoglycemia rates,” the authors write.<\/p>\n Several authors disclosed ties to Dexcom.<\/p>\n Abstract\/Full Text<\/a><\/p>\n